METI-DERM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Meti-derm, and when can generic versions of Meti-derm launch?
Meti-derm is a drug marketed by Schering and is included in one NDA.
The generic ingredient in METI-DERM is prednisolone. There are eighty-eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the prednisolone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Meti-derm
A generic version of METI-DERM was approved as prednisolone by WATSON LABS on December 31st, 1969.
Summary for METI-DERM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 94 |
Patent Applications: | 4,672 |
Formulation / Manufacturing: | see details |
DailyMed Link: | METI-DERM at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for METI-DERM
US Patents and Regulatory Information for METI-DERM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | METI-DERM | prednisolone | CREAM;TOPICAL | 010209-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for METI-DERM
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
LE VET B.V. | Equisolon | Prednisolone | EMEA/V/C/002382 Alleviation of inflammatory and clinical parameters associated with recurrent airway obstruction (RAO) in horses, in combination with environmental control. |
Authorised | no | no | no | 2014-03-12 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |